Search
for
Sort by
Research 91–120 of 140
- Involvement of ILC1-like innate lymphocytes in human autoimmunity, lessons from alopecia areata
- Laser Capture Microdissection Reveals Transcriptional Abnormalities in Alopecia Areata before, during, and after Active Hair Loss
- Alopecia Areata: A Review of the Role of Oxidative Stress, Possible Biomarkers, and Potential Novel Therapeutic Approaches
- Immunopathology and Immunotherapy of Inflammatory Skin Diseases
- Epigallocatechin-3 Gallate Inhibits STAT-1/JAK2/IRF-1/HLA-DR/HLA-B and Reduces CD8 MKG2D Lymphocytes of Alopecia Areata Patients
- Wharton’s jelly-derived mesenchymal stem cells in the treatment of four patients with alopecia areata
- Immune therapies for alopecia areata: evidence and new perspectives
- From mechanisms to therapies: current advances breakthroughs in alopecia areata immunopathology
- The genetic link between thyroid dysfunction and alopecia areata: a bidirectional two-sample Mendelian randomization study
- Inflammatory loops in the epithelial–immune microenvironment of the skin and skin appendages in chronic inflammatory diseases
- Regulation and dysregulation of hair regeneration: aiming for clinical application
- Dermal T cell immunity and key regulatory signaling pathways: Implications in immune-mediated alopecia and hair regeneration
- Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs
- Clinical and Genetic Aspects of Alopecia Areata: A Cutting Edge Review
- Real World Evidence in Alopecia Areata: Current Management, Emerging Therapies and Future Challenges – A Narrative Review
- Genome-wide association study of atopic and autoimmune comorbidities in alopecia areata
- Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience
- Ophthalmologic Comorbidities in Alopecia Areata
- Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review
- Research progress in the treatment of non-scarring alopecia: mechanism and treatment
- Alopecia Areata Incognita: Current Evidence
- Alopecia Areata: Understanding the Pathophysiology and Advancements in Treatment Modalities
- Pathogenesis and regenerative therapy in vitiligo and alopecia areata: focus on hair follicle
- Pathogenesis of Alopecia Areata and Vitiligo: Commonalities and Differences
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Alopecia areata in children: an overview of clinical features and recent treatment options
- Editor's evaluation: Involvement of ILC1-like innate lymphocytes in human autoimmunity, lessons from alopecia areata
- Alopecia areata: a review of diagnosis, pathogenesis and the therapeutic landscape
- A perspective on predictive markers of alopecia
- Topical JAK Inhibitors for the Treatment of Alopecia Areata and Vitiligo